Literature DB >> 2862938

The in vitro pharmacology of xamoterol (ICI 118,587).

E Malta, M A Mian, C Raper.   

Abstract

The effect of xamoterol and (-)-isoprenaline have been compared for their activity at beta-adrenoceptor sites in a number of in vitro cardiac and smooth muscle preparations. Xamoterol produced weak positive chronotropic effects in guinea-pig, rat and cat atria (intrinsic activity less than 0.55, (-)-isoprenaline = 1). Positive inotropic effects were obtained in driven left atria of the cat but were absent in guinea-pig left atrial and right ventricular strip preparations. Agonistic effects were due to beta 1-adrenoceptor stimulation. Xamoterol was without beta-adrenoceptor-mediated inhibitory effects in guinea-pig ileal, tracheal and uterine preparations and in the rat vas deferens and oestrogen-primed uterus. Weak beta 2-adrenoceptor-mediated relaxation was obtained in progesterone-primed rat uteri. Xamoterol produced non-specific inhibitory effects in guinea-pig ileal and tracheal preparations. Xamoterol acted as a competitive antagonist at beta 1-(pA2 range = 7.4 to 7.8) and beta 2-adrenoceptors (pA2 range 5.2 to 6.2) and displaced [125I]-iodocyanopindolol from guinea-pig left atrial (pKD = 7.25) and uterine (pKD 5.24) membrane preparations. It is concluded that xamoterol displays a selective affinity for beta 1-adrenoceptors. Although its partial agonistic actions are more evident at beta 1-adrenoceptor sites, like prenalterol, xamoterol displays a degree of tissue rather than receptor-dependent selectivity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2862938      PMCID: PMC1916765          DOI: 10.1111/j.1476-5381.1985.tb08845.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

1.  Pharmacological approaches to the characterization of beta-adrenoreceptor populations in tissues.

Authors:  S R O'Donnell; J C Wanstall
Journal:  J Auton Pharmacol       Date:  1981-09

2.  Is prenalterol (H133/80) really a selective beta 1 adrenoceptor agonist? Tissue selectivity resulting from differences in stimulus-response relationships.

Authors:  T P Kenakin; D Beek
Journal:  J Pharmacol Exp Ther       Date:  1980-05       Impact factor: 4.030

3.  In vitro activity of RO363, a beta1-adrenoceptor selective agonist.

Authors:  D Iakovidis; E Malta; G A McPherson; C Raper
Journal:  Br J Pharmacol       Date:  1980-04       Impact factor: 8.739

4.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

5.  Non-catechol phenylethanolamines: agonistic and antagonistic actions on beta-adrenoreceptors in isolated tissues from the guinea-pig.

Authors:  E Malta; C Raper
Journal:  Clin Exp Pharmacol Physiol       Date:  1974 May-Jun       Impact factor: 2.557

6.  Interactions of sympathomimetic drugs, propranolol and phentolamine, on atrial refractory period and contractility.

Authors:  B G Benfey; D R Varma
Journal:  Br J Pharmacol Chemother       Date:  1967-08

7.  Prenalterol is an agonist at beta 2- as well as at beta 1-adrenoceptors.

Authors:  G H Apperley; G M Drew; A T Sullivan
Journal:  Eur J Pharmacol       Date:  1982-07-30       Impact factor: 4.432

8.  Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols.

Authors:  J J Barlow; B G Main; H M Snow
Journal:  J Med Chem       Date:  1981-03       Impact factor: 7.446

9.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

10.  Pre- and postjunctional effects of clonidine- and oxymetazoline-like compounds in guinea-pig ileal preparations.

Authors:  E Malta; C Raper; P E Tawa
Journal:  Br J Pharmacol       Date:  1981-06       Impact factor: 8.739

View more
  7 in total

Review 1.  Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  R Furlong; R N Brogden
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

Review 2.  The pharmacology of xamoterol: a basis for modulation of the autonomic control of the heart.

Authors:  H M Snow
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

3.  Myocardial, coronary, and peripheral effects of xamoterol (ICI 118,587) in open-chest pigs.

Authors:  N Galiè; M Metalli; R Zannoli; G Binetti; A Branzi; B Magnani
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

4.  Preliminary study of the efficacy of xamoterol in bradycardia-tachycardia syndrome.

Authors:  N Mizutani; T Kobayashi; T Watanabe
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

5.  Xamoterol impairs hippocampus-dependent emotional memory retrieval via Gi/o-coupled β2-adrenergic signaling.

Authors:  Keith Schutsky; Ming Ouyang; Steven A Thomas
Journal:  Learn Mem       Date:  2011-08-30       Impact factor: 2.460

6.  Selective and full beta 1-adrenoceptor agonist action of a catechol derivative of denopamine (T-0509) in the guinea-pig cardiac muscle and trachea: comparison with denopamine, xamoterol and isoprenaline.

Authors:  H Yabana; H Watanabe; H Narita; T Nagao
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

7.  Beta-adrenoceptor antagonists increase sinus arrhythmia, a vagotonic effect.

Authors:  S B Bittiner; S E Smith
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.